Date: 2014-01-30
Type of information: Licensing agreement
Compound: X-MAN™ cell lines
Company: Horizon Discovery (UK) undisclosed Japanese medical university (Japan)
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: Horizon’s X-MAN isogenic cell lines accurately model the disease-causing mutations found in patients with cancer, and increasingly other diseases. Horizon creates these cell lines using its genome-editing GENESIS™ platform, consisting of rAAV, ZFN and CRISPR technologies, to engineer specific disease-related mutations. These models help researchers understand how complex genetic diseases manifest themselves in patients, and can reduce the cost of bringing to market new personalized therapies by streamlining many aspects of drug development including target identification, target validation, assay development, drug screening, lead optimization, and biomarker-driven clinical trial design.
Disease:
Details: * On January 30, 2014, Horizon Discovery, a provider of research tools to support translational genomics and the development of personalized medicines, has announced it has entered into a large-scale licensing agreement with a Japanese medical university. The agreement covers a limited use label license for academic use of 250 of Horizon’s X-MAN™ genetically defined, isogenic cell lines, and demonstrates the global recognition of the company’s in vitro disease models.
Financial terms:
Latest news:
